Literature DB >> 7747525

[Mumps epidemiology in Switzerland: results from the Sentinella surveillance system 1986-1993. Sentinella Work Group].

H Zimmermann1, H C Matter, T Kiener.   

Abstract

UNLABELLED: Since 1990, there have been reports of an increasing number of mumps cases in Switzerland, in particular among vaccinated children, and of local outbreaks of mumps. Using data from the Sentinella reporting system, a network of voluntary participating doctors (general practitioners, internists and paediatricians, yearly average: n = 141), trends and factors influencing mumps incidence in the general population were assessed during the last seven years. Following an initial decline in mumps reports, since 1990, there has been a continuous and marked increase in reports from a minimum of 0.7 cases per physician and year in 1989/90 to a near five-fold increase of 3.3 cases in the last reporting period from June-December 1993 (calculated for one year). Half of this increase, which is reflected in a doubling of the number of cases reported in 1986/87, is explained by an increase in cases among vaccinated children. The trend in mumps cases contrasts with that of measles and rubella, where there has been a clear decline in these reports since 1986 (approximately 70-80%). Complications were reported in 75 (4.0%) of the total number of mumps patients (n = 1894); in 2/5 of the cases this was a meningitis, in 1/3 an orchitis. Based on available data on vaccination coverage, the estimated efficacy of the mumps vaccines against parotitis is between 47-77%; this is clearly lower than the corresponding figure for measles (91-97%) and rubella (89-97%) vaccines. The relatively low efficacy against parotitis is mainly due to a protective level of 13-73% of the vaccines containing the Rubini strain. The estimated efficacy of the Rubini vaccines against complications is 50-81%; it is nearly 60-90% if a possible reporting bias is taken into consideration.
CONCLUSIONS: 1. The Rubini strain vaccines, which are the most commonly used in Switzerland, seem to have played an important role in the clear increase in mumps cases since 1990. 2. The situation seems more favourable concerning the efficacy against complications of the vaccines used. 3. Our data support the high efficacy of all measles and rubella vaccines. 4. The surveillance of MMR by the Sentinella reporting system provides a useful and effective manner to evaluate the MMR vaccination programme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747525     DOI: 10.1007/BF01360322

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  19 in total

1.  [Vaccination and morbidity in Basel school-children (measles, mumps, rubella, chickenpox, cytomegalic inclusion disease)].

Authors:  A Bächlin; R Berger-Hernandez; M Just
Journal:  Soz Praventivmed       Date:  1978-08

2.  Mumps outbreak in a highly vaccinated population.

Authors:  B S Hersh; P E Fine; W K Kent; S L Cochi; L H Kahn; E R Zell; P L Hays; C L Wood
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

Review 3.  Assessing vaccine efficacy in the field. Further observations.

Authors:  W A Orenstein; R H Bernier; A R Hinman
Journal:  Epidemiol Rev       Date:  1988       Impact factor: 6.222

4.  [Immunization coverage at the start of compulsory school attendance].

Authors:  V Woringer
Journal:  Rev Med Suisse Romande       Date:  1989-05

5.  The effect of a school entry law on mumps activity in a school district.

Authors:  B P Chaiken; N M Williams; S R Preblud; W Parkin; R Altman
Journal:  JAMA       Date:  1987-05-08       Impact factor: 56.272

6.  The efficiency of measles and pertussis notification in England and Wales.

Authors:  J A Clarkson; P E Fine
Journal:  Int J Epidemiol       Date:  1985-03       Impact factor: 7.196

7.  [Immune response to various antiviral vaccines].

Authors:  R Tabin; J P Berclaz; G Dupuis; O Peter
Journal:  Rev Med Suisse Romande       Date:  1993-12

8.  Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity.

Authors:  P A Briss; L J Fehrs; R A Parker; P F Wright; E C Sannella; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

9.  Clinical mumps vaccine efficacy.

Authors:  R Kim-Farley; S Bart; H Stetler; W Orenstein; K Bart; K Sullivan; T Halpin; B Sirotkin
Journal:  Am J Epidemiol       Date:  1985-04       Impact factor: 4.897

10.  Perspectives on the relative resurgence of mumps in the United States.

Authors:  S L Cochi; S R Preblud; W A Orenstein
Journal:  Am J Dis Child       Date:  1988-05
View more
  3 in total

1.  [Comparison of the efficacy of various strains of mumps vaccine: a school survey].

Authors:  L Toscani; M Batou; P Bouvier; A Schlaepfer
Journal:  Soz Praventivmed       Date:  1996

2.  [A look back at 2 mumps outbreaks].

Authors:  M F Paccaud; P Hazeghi; M Bourquin; A M Maurer; C A Steiner; A J Seiler; P Helbling; H Zimmermann
Journal:  Soz Praventivmed       Date:  1995

Review 3.  [Mumps epidemiology--worldwide].

Authors:  C Herzog
Journal:  Soz Praventivmed       Date:  1995
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.